biotech.today

Details

  • ●Modalities: small molecules, precision oncology
  • ●Therapeutic areas: oncology, immunology, neuroscience
  • ●Key targets: CDK7, PKC theta, MALT1, A2A receptor, LSD1
  • ●Indications: solid tumors, hematological malignancies, autoimmune diseases
  • ●Funding: $688M (acquisition value)

Partners & investors

  • Recursion Pharmaceuticals (acquirer)· Investor
  • SoftBank Vision Fund (pre-acquisition)· Investor
  • Evotec (pre-acquisition)· Investor
  • BMS (partner)· Investor

Key considerations

  • ●AI tools in use: Centaur Chemist (AI-human drug design), Automated synthesis lab (Oxford), Patient-tissue derived models, Precision medicine biomarker platform
  • ●First AI-designed drug to enter clinical trials (DSP-1181, with Sumitomo, 2020)
  • ●Acquired by Recursion for $688M (Nov 2024)
  • ●Sanofi partnership ($5.2B potential, 2022)

Pipeline

  • Phase 12
Get live updates on Exscientia’s hiring, filings, and partnerships. Follow in BT Pro →
Source: Company website, SEC / Companies House filings, press releases, Crunchbase · biotech.today analysis (Apr 2026)

Key people

Andrew Hopkins

Founder & Former CEO

computational chemistryAI drug discoverymedicinal chemistry

Dave Hallett

Chief Scientific Officer

medicinal chemistrydrug designstructure-activity
Visit website →LinkedIn →